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Cancer evolutionSince initial discovery of the ﬁrst HSP90 inhibitor over a decade and a half ago, tremendous progress has been
made in developing potent and selective compounds with which to target this chaperone in the treatment of
cancers. These compounds have been invaluable in dissecting how HSP90 supports the dramatic alterations
in cellular physiology that constitute the malignant phenotype and give rise to the clinical manifestations of
diverse cancers. Unfortunately, single agent activity for HSP90 inhibitors has been disappointingly modest
against recurrent, refractory cancers in most of the clinical trials that have been reported to date. This problem
could be due to pharmacological limitations of the ﬁrst-generation inhibitors that have been most extensively
studied. But we suggest it may well be intrinsic to the target itself. This review will focus on how the utilization
of HSP90 by cancer cells might be targeted to enhance the activity of other anticancer drugs while at the same
time limiting the ability of advanced cancers to adapt and evolve drug resistance; the net result being more du-
rable disease control. A better understanding of these fundamental issues will surely make the ongoing clinical
development of HSP90 inhibitors as anticancer drugs less empiric, more efﬁcient and hopefully more successful.
This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).
© 2012 Elsevier B.V. All rights reserved.“It is not enough to know that changes in DNA can in some unknown
way cause a change in phenotype; we need to know at least in outline
how phenotypes respond to particular changes in DNA. It is this third
pillar, an understanding of the organism's response to genetic change,
that is our subject here and the resolution to Darwin's dilemma.”
M.W. Kirschner and J.C. Gerhart
The Plausibility of Life, 20051. Introduction
Over the last three decades, great progress has been made in un-
derstanding the molecular mechanisms that drive carcinogenesis. In
a wide range of different cancers, hundreds of speciﬁc genes and pro-
teins have been implicated and the biochemical functions of many of
these deﬁned. Unfortunately, potent and selective agents designed to
target speciﬁc oncoproteins such as HER2 in breast cancer [1], thehock Protein 90 (HSP90).
+1 617 258 7226.
l), Nancy_Lin@dfci.harvard.edu
l rights reserved.fusion kinase BCR–ABL in chronic myeloid leukemia [2] and the
EGFR in non-small cell lung cancer [3,4] are proving less efﬁcacious
than had been hoped due to the intrinsic complexity of molecular on-
cogenesis and the frequent emergence of resistance, especially in ad-
vanced disease. Much of the same can be said of older conventional
chemotherapeutics that target DNAmetabolism and cellular replication
through a variety of distinct mechanisms. Although drug efﬂux pumps
can play a role in acquired resistance to these agents, speciﬁc target-
related mechanisms are often the primary culprit.
Within the array of drugs and macromolecules now advancing
through the process of clinical development, compounds that target
the functions of Heat Shock Protein 90 (HSP90) are unique. As a mul-
tifunctional molecular chaperone, HSP90 regulates the post-
translational stability and function of a distinct but diverse set of “client”
proteins known to be critically involved in oncogenesis. Much of the
current enthusiasm driving the discovery and development of HSP90
inhibitors has been generated by their potential to accomplish what
many molecularly targeted anticancer therapies do not: the simulta-
neous disruption of multiple signaling pathways critical to tumor cell
growth and survival. Such a combinatorial attack on the oncogenic cli-
ents of HSP90 has been proposed to represent a “rational approach” to
addressing the heterogeneity and complexity of the numerous genetic
defects characteristic of most clinical cancers [5].
Unfortunately, single agent activity for HSP90 inhibitors has been
disappointingly modest against recurrent, refractory cancers in the
Phase I and Phase II clinical trials that have been reported to date.
This problem could be due to pharmacological limitations of the
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But we suggest it may well be intrinsic to the target itself. In this re-
view, we will examine the concept that the best way to exploit
HSP90 as a therapeutic target will be in combination with other anti-
cancer agents. Analogous to the cellular role HSP90 plays as a plat-
form for the assembly of multi-protein chaperone complexes, we
suggest HSP90 inhibition can serve as a platform for the assembly of
speciﬁc multi-drug chemotherapeutic regimens that will more effec-
tively control disparate cancers (Fig. 1). This approach leverages what
is known about the adaptive roles that HSP90 plays in rendering cells
and organisms more robust to lethal challenges. In cancers, such chal-
lenges can arise as a result of the harsh tumor microenvironment,
therapeutic interventions and alterations to normal physiology driven
by malignant transformation. In buffering the phenotypic expression
of genetic variation and sculpting the architecture of entire signaling
networks, HSP90 plays an essential role in enabling tumor progression
without being an oncogene in the classical sense of driving the process
itself. Perhaps not terribly surprising then, HSP90 inhibitors as single
agents have exerted predominantly cytostatic effects in most tumor
models and clinical trials to date.
To provide a somewhat different perspective from the other re-
views in this special issue, we will focus on how the utilization of
HSP90 by cancer cells might be targeted to enhance the activity of
other anticancer drugs while at the same time limiting the ability of
advanced cancers to adapt and evolve drug resistance; the net result
being more durable disease control. Rather than provide deﬁnitive
answers, our goal is to stimulate further discussion and investigation
by translational scientists. Addressing these fundamental issues will
surely make the ongoing clinical development of Hsp90 inhibitors
as anticancer drugs less empiric, more efﬁcient and hopefully more
successful.
2. Basic insights
2.1. Enhancing the activity of drugs with disparate anticancer mechanisms
Decades of careful investigation encompassing many different
ﬁelds have provided a wealth of biochemical and structural knowl-
edge about HSP90 and its interaction with its client proteins [6]. Never-
theless, our understanding of HSP90 function and how it is altered in
various cancers remains far from complete. In particular the conse-
quences of inhibiting HSP90 function for cellular processes other than
mitogenic signaling, such as protein homeostasis, energy metabolism,
chromatin re-modeling and DNA repair are just beginning to get
much deserved consideration [5]. Drug-induced changes in these as-
pects of physiology have also been largely ignored in the clinical devel-
opment of HSP90 inhibitors which has largely been driven by a “super
kinase inhibitor” orientation in guiding the selection of speciﬁc disease
histologies for inclusion in Phase II studies [7]. This strategy has led to
some notable successes in patients with tumors driven by activating
mutations (e.g. EML4–ALK in non-small cell lung cancer) and gene am-
pliﬁcation (e.g. HER2 in breast cancer). A broader view, however, is re-
quired in planning how best to combine HSP90 inhibitors with other
chemotherapeutics. In this regard, HSP90 inhibitors serve as an excel-
lent paradigm for thinking more generally about therapeutic interven-
tions as “perturbagens” that modulate not just their immediate target,
but rather the function of entire cellular systems to generate their de-
sired therapeutic effects [8–10].
2.1.1. Conventional chemotherapeutics
In cell culture models, combining HSP90 inhibitors with cytotoxic
agents has the broad ability to increase their anticancer activity by a
host of molecular mechanisms that are still being elucidated. In the
case of alkylating agents and antimetabolites, sensitization appears
to involve HSP90 inhibitor-mediated depletion of CHK1 and WEE1
to abrogate S and G2/M cell cycle checkpoint controls in a p53-independent manner [11]. Disruption of these checkpoints is also
thought to underlie sensitization to topoisomerase I inhibitors such
as irinotecan [12]. Similarly, HSP90 inhibitors have been shown to
act as radio-sensitizers in pre-clinical models, again independent of
p53 and probably related to impairment of cell cycle checkpoints
and DNA repair mechanisms [13]. Instead of checkpoint disruption,
sensitization to etoposide and other topoisomerase II poisons is
reported to occur through release of a repressive interaction between
HSP90 and the topoisomerase leading to an increase in active enzyme
and the ability of etoposide to induce more DNA damage [14]. Interest-
ingly, cisplatin, which adducts DNA, may also attack reactive cysteines
in the C-terminus of HSP90 and impair its chaperone function [15].
When used in combination with classical N-terminal-binding inhibi-
tors, this could result in more profound inhibition of the chaperone's
functions. An added advantage could be that cisplatin exposure also
blocks the compensatory up-regulation of heat shock protein expres-
sion induced by classical HSP90 inhibitors [16,17]. The mechanism re-
mains undeﬁned, but inhibiting this cytoprotective response has been
proposed as a strategy to increase the anticancer activity of HSP90 in-
hibitors [18]. Whether it would also increase their systemic toxicity is
not clear.
In the case of microtubule poisons, mitotic catastrophe is exacer-
bated by HSP90 inhibition in cell lines with defects in the function
of BRCA1 [19] or RB [20]. Interference with the role of HSP90 in cen-
trosome organization presumably underlies this effect [21,22]. In an
interesting twist, the microtubule poison docetaxel has been reported
to impair HSP90 chaperone function by causing its dissociation from
tubulin, thereby stimulating proteasome-mediated degradation of
the chaperone itself. The extent to which this novel activity contrib-
utes to the established anticancer activity of docetaxel in patients is
unknown [23]. It is intriguing, however, that the clinical activity of
classical cytotoxic agents such as cisplatin and docetaxel may well
be mediated or at least enhanced to some degree by their effects on
HSP90 function.
Overlaid on mechanisms speciﬁc to different chemotherapeutic
classes, HSP90 inhibitors are well recognized to disrupt the function
of AKT and other key survival signaling molecules [16,24–27]. This ac-
tivity can lower the set-point for induction of programmed cell death
by both conventional and targeted agents. It may also directly coun-
teract the anti-apoptotic effects of commonly occurring oncogenic le-
sions such as loss of PTEN function that contribute to drug resistance
[28,29]. Indeed, a recent pharmacokinetic–pharmacodynamic study
of the HSP90 inhibitor PF04942847 found that of all HSP90 clients ex-
amined, inhibition of AKT was the biomarker most predictive of anti-
tumor activity in a human breast cancer xenograft model [30].
2.1.2. Kinase inhibitors
Many potent drugs designed to selectively inhibit speciﬁc onco-
genic kinases are now in clinical development for the treatment of a
variety of cancers. Some are proving highly active, inducing impres-
sive responses in cancers with the relevant underlying molecular pa-
thology. Some have even become the standard of care in certain
malignancies such as the BCR–ABL inhibitor imatinib in chronic mye-
loid leukemia (CML) [31]. Unfortunately, all are proving less efﬁca-
cious than had been hoped. In advanced disease, responses are
often profound, but temporary [32]. The mechanisms that underlie
both initial sensitivity and acquired resistance to kinase inhibitors
vary with the speciﬁcs of tumor type and drug, but at least two general
principles are emerging. First, in genetically unstable tumor cell popula-
tions, drug pressure can efﬁciently select for mutations in the targeted
kinase that diminish drug binding but preserve oncogenic activity. Sec-
ond, activation of by-pass signaling pathways can allow cancer cells to
rapidly become less dependent on the drug target for growth and sur-
vival, so-called oncogenic switching [33] . To address the ﬁrst problem,
next generation kinase inhibitors have been synthesized based on
structural insights provided by isolation of drug-resistant mutants
Fig. 1. HSP90 inhibition as a platform on which to assemble more effective chemotherapeutic regimens. The utilization of HSP90 by cancer cells in avoiding apoptosis, maintaining
homeostasis, buffering mutations and supporting the function of oncogenic clients might be targeted to enhance the activity of other anticancer drug classes while at the same time
limiting the ability of cancers to adapt and evolve drug resistance; the net result being more durable disease control.
758 L. Whitesell, N.U. Lin / Biochimica et Biophysica Acta 1823 (2012) 756–766from patients. These impressive efforts provide a reprieve, but in CML
for example, the emergence of resistance to second generation inhibi-
tors is being reported and the development of third generation inhibi-
tors is underway [34]. Suggested strategies to address the bypass
problem have typically involved the use of inhibitor cocktails or so-
called “dirty” inhibitors that are more promiscuous in the targets they
inhibit. The goal is to block bypass pathways, but the effort comes at
the cost of escalating toxicity [32,35].
What is the relevance of this clinical experience with selective ki-
nase inhibitors to the development of HSP90 inhibitors? In regard to
drug-resistant mutant kinases, considerable pre-clinical evidence in-
dicates they remain fully sensitive to disruption by HSP90 inhibitors.
In fact, mutations that confer resistance often have conformation
destabilizing effects that lead to increased dependence on HSP90 for
function and increased sensitivity to HSP90 inhibition [36]. In regard
to bypass pathways, the role of HSP90 in modulating entire signaling
networks suggests that inhibiting it could limit the ability of tumor
cells to adapt and respond when their addiction to a particular kinase
is acutely challenged by exposure to inhibitor. Outgrowth of resistant
clones would be reduced and the duration of disease control prolonged.
Salvage therapy with HSP90 inhibitors for kinase inhibitor treat-
ment failures is being pursued in a variety of diseases including
CML, melanoma, GI stromal tumors, and lung cancer (see Table 1
and [37,38]). Pragmatically, this approach may be necessary given
the constraints of the clinical trial process, but conceptually it is
ﬂawed. Rather than permit highly drug-resistant clones to accumu-
late and then attempt to eradicate them, combined exposure upfront
could prevent their emergence in the ﬁrst place. Pre-clinical data in
CML support this position. Low dose exposure to an HSP90 inhibitor
dramatically reduced the emergence of BCR–ABL kinase mutants in
a bulk cell population selected for resistance to imatinib [39].
2.1.3. Other classes
The ATPase cycle of HSP90 can also be inhibited by acetylation of
lysine residues within the protein. Histone deacetylase 6 (HDAC6)
co-puriﬁes with Hsp90 and HDAC6 knockdown promotes the deple-
tion of several known Hsp90 clients [40]. Thus, it appears that
HDAC inhibitors such as vorinostat (suberoylanilide hydroxamic
acid) which are currently undergoing clinical evaluation based on
their ability to alter chromatin structure and gene expression mayalso exert anticancer activity in part through HSP90 inhibition
[41,42]. Pre-clinical data demonstrate that combined exposure to
HDAC inhibitor and a classical N-terminal HSP90 inhibitor results in
more profound compromise of HSP90 chaperone activity and greater
anticancer activity [43].
Beyond its stabilization of speciﬁc oncogenic clients, Hsp90 plays a
role in maintaining protein homeostasis in the cell by cooperating
with the ubiquitin–proteasome system to degrade a wider range of
misfolded proteins [44]. When combined with an inhibitor of the pro-
teasome, HSP90 inhibitors can overload the protein degradation ma-
chinery and drive induction of apoptosis in susceptible cell types.
Presumably due to enormous ﬂux through the secretory pathway of
immunoglobulin-secreting myeloma cells, this tumor type is very
sensitive to dual inhibition of HSP90 and the proteasome [45]. The
role of HSP90 in chaperoning components of the phosphoinositol 3-
kinase (PI-3K)–mTOR pathway such as AKT has prompted studies
combining HSP90 inhibitors with rapamycin and other compounds
targeting this pathway to increase their anticancer activity [46–48].2.2. Limiting the emergence of target-related resistance
2.2.1. Resistance as an evolutionary process
Efforts to improve the efﬁcacy of current chemotherapeutic regi-
mens are plagued by the inescapable genetic heterogeneity and evol-
vability of human cancers [49,50]. It is crucial to bear in mind that
cancers, while monoclonal in origin, are characterized by high rates
of mutation and frequent aneuploidy [51]. They are not static multi-
genic diseases with a limited, deﬁnable set of targets. Instead, clinical
cancers are heterogeneous populations, among which arise cells that
are ever better adapted to evading host defense mechanisms, to popu-
lating new environments, and to resisting therapeutic attacks. The
total number of genomic alterations per typical carcinoma cell is esti-
mated to be roughly 10,000 even though only 5–10 speciﬁc genetic al-
terations are sufﬁcient for malignancy [52,53]. As cancers evolve along
multiple pathways, driven by intense selective pressures in the host,
they exploit a cache of pre-existing and newly acquired genetic varia-
tion to do so. Viewed in this light, cancer evolution within an individual
host is driven by the very same pressures of natural selection that drive
the macroevolution of organisms and populations in nature.
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tumor progression and what might be the consequences of inhibiting
it on the emergence of drug resistance? As a direct consequence of its
protein chaperoning activity, HSP90 permits polymorphic variants of
critical signaling molecules and transcription factors to retain uniform
“wild type” biochemical activity. This “buffering” at the protein level
by HSP90 funnels complex developmental processes into discrete,
well-deﬁned outcomes despite underlying genotypic variation, and
it appears to be essential for the robust expression of uniform pheno-
types under basal conditions [54,55]. Under stressful conditions,
however, some unstable client proteins of HSP90 are likely to become
even more unstable. This problem creates an increased demand for
HSP90 to facilitate the refolding of its usual client proteins as well
as new, mutant or stress-destabilized clients. The accumulated genetic
variation in certain individuals can thereby exceed the buffering capac-
ity of HSP90 and produce diverse, but genotype-speciﬁc phenotypes
[56]. Effects on the manifestation of underlying genetic variation have
beendemonstrated forHSP90 inhibition in a variety ofmetazoanorgan-
isms ranging from fruit ﬂies [57] to plants [58] and zebraﬁsh [59]. Re-
vealing previously hidden genetic variation makes it available at the
phenotypic level for natural selection to enhance the survival of distinct
genotypes within a population [60]. Recently additional mechanisms
have been described bywhich HSP90 and other chaperones can impact
phenotypic diversity. These include effects on the heritability of epige-
netic traits [55], the tolerance of protein structures to mutation [61]
and even the activity of regulatory genetic elements [62].
Viewed from an evolutionary perspective, a tumor can be viewed
as a large, genetically and epigenetically heterogeneous population ofTable 1
HSP90 inhibitor clinical trials.
Class Compound Route Manufacturer Phase Current status
Geldanamycin
derivative
Tanespimycin
(17-AAG)
IV BMS II/III No longer being
Alvespimycin
(17-DMAG)
IV Kosan/BMS I Multiple phase
Retaspimycin
(IPI-504)a
IV Inﬁnity II/III Multiple phase
III trial in GIST t
ongoing (NCT01
ABI-010 (albumin-
nano-particle 17-AAG)
IV Abraxis I No active trials
IPI-493 (17-AG) PO Inﬁnity I Two phase I stu
Resorcinol
scaffold
Ganetespib (STA-
9090)
IV Synta II/III Multiple ongoin
(NCT01273896)
pancreatic canc
(NCT01031225)
in NSCLC (NCT0
AUY922 IV Novartis I/II Multiple phase
combination stu
erlotinib (NCT0
Other small
molecule
SNX-5422 PO Pﬁzer I Development h
AT13387 PO or
IV
Astex I/II Several ongoing
randomized pha
BIIB021c PO Biogen Idec I Multiple phase
cancer with tras
BIIB028 IV Biogen Idec I Phase I no longe
KW-2478 IV Kyowa Hakko
Kirin
I/II Phase I in multi
myeloma ongoi
XL888 PO Exelixis I Phase I termina
NVP-HSP990 PO Novartis I Phase I studies
MPC-3100d PO Myriad I Phase I no longe
DS-2248 PO Daiichi Sankyo I Single agent, so
Debio 0932 PO Debiopharm I Single agent, ad
PU-H71 IV Memorial
Sloan-
Kettering
I Single agent, ad
a http://www.reuters.com/article/2011/05/19/idUS132232+19-May-2011+GNW201105
b Rajan, A., et al., A phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable he
lymphomas, Clin Cancer Res, Published OnlineFirst September 9, 2011; doi:10.1158/1078-0
c Lundgren, K., et al., BIIB021, an orally available, fully synthetic small-molecule inhibitor
d M. K. Yu, W. E. Samlowski, V. Baichwal, B. Brown, B. A. Evans, D. Woodland, G. Mather, A.
Hsp90 inhibitor in cancer patients, J Clin Oncol, 28, 2010 (suppl; abstr e13112).cells [63]. We propose that HSP90 acts as a biochemical buffer at the
protein level for this extensive heterogeneity to maintain cell viability
and limit phenotypic variation, a process known in developmental
biology as canalization. During the natural history of cancer progres-
sion, however, canalization of the malignant phenotype could break
down when HSP90 capacity is exceeded as a result of normal aging,
an increasing load ofmutant and/ormisfolded oncoproteins, or the hos-
tile tumor microenvironment— or more likely, all these factors in con-
cert. Epigenetic instability and phenotypic diversity within the tumor
cell population would increase and accelerate the emergence of inva-
sive, metastatic and drug-resistant biologies [64,65]. Such an evolution-
ary view of tumor progression ﬁts well with the clinical behavior of
manymalignancies and suggests that durable control of clinical cancers
is likely to be achieved only by limiting their ability to adapt and evolve
[49]. How HSP90 inhibitors might impact tumor evolution is not
known. As would be expected, clinical trials of all the investigational
HSP90 inhibitors in development have been restricted to patients
with advanced, refractory malignancies.
Most cancers progress from benign, relatively well-differentiated
tumors to increasingly invasive and metastatic cancers characterized
by profound genomic instability and the accumulation of numerous
genetic alterations [66]. The role of HSP90 might shift as cells move
through the initiation phase to the progression phases of tumorigenesis.
If so, inhibiting HSP90 could have profoundly different effects on
early stage lesions versus advanced cancers. It could be important
to assess the status of the HSP90 reservoir in a particular tumor
prior to initiating therapy with an inhibitor. The level of HSP90 pro-
tein in non-small-cell lung cancers has recently been shown todeveloped.
I studies completed, including in combination with trastuzumab.
I/II trials completed in castrate resistant prostate cancer, breast cancer, NSCLC. Phase
erminated for toxicity. Randomized phase II of docetaxel +/−IPI-504 in NSCLC
362400).
listed in www.clinicaltrials.gov
dies completed. Development halted as drug exposure was inferior to retaspimycin
g phase II trials in castrate resistant prostate cancer (NCT01270880), breast cancer
, hematologic malignancies (NCT0084872), esophagogastric cancer (NCT01167114),
er (NCT01227018), melanoma (NCT01200238), SCLC (NCT01173523), NSCLC
, GIST (NCT01039519). Ongoing randomized Phase II/III of docetaxel +/−STA-9090
1348126).
II trials: NSCLC (NCT01124864), breast cancer (NCT00526045). Multiple ongoing
dies: bortezomib (NCT00708292), trastuzumab (NCT01271920; NCT01402401),
1259089), cetuximab (NCT01294826), capecitabine (NCT01226732).
alted due to excessive ocular toxicity.b
phase I in solid tumors (NCT00878423, NCT01245218, NCT01246102). Ongoing
se II +/−imatinib in GIST (NCT01294202).
I trials in solid tumors and CLL completed. Phase I combination studies in breast
tuzumab, exemestane no longer recruiting.
r recruiting. No other trials listed in clinicaltrials.gov.
ple myeloma, CLL, NHL completed. Phase I/II trial in combination with bortezomib for
ng (NCT01063907)
ted. No active trials listed in clinicaltrials.gov.
ongoing in advanced solid tumors (NCT01064089; NCT00879905)
r recruiting. No other trials listed in clinicaltrials.gov
lid tumors (NCT01288430)
vanced solid tumors/lymphoma (NCT01168752)
vanced solid tumors/lymphoma (NCT01393509)
19.
at shock protein 90 inhibitor in patients with refractory solid tumor malignancies and
432.CCR-11-0821.
of the heat shock protein Hsp90, Mol Cancer Ther, 2009. 8(4): 921−9.
Patnaik, A. W. Tolcher, K. Papadopoulos, MPC-3100, a fully synthetic, orally bioavailable
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evaluated as a predictor of response to HSP90 inhibitor therapy in
this or any other cancer type. An increase in the level of the highly in-
ducible chaperone HSP72 in surrogate normal tissue or even tumor
tissue has been used as a sensitive pharmacodynamic endpoint for
HSP90 inhibition in many clinical trials. Unfortunately, it clearly
fails to predict anticancer response.
The frustrating lack of predictive markers may arise, to a great ex-
tent because HSP90 does not act alone, but rather as part of a complex
network of additional heat shock proteins, co-chaperones and acces-
sory molecules [5,6]. The expression level of co-chaperones such as
AHA1 and CDC37 has been shown to affect the sensitivity of cancer
cell lines to HSP90 inhibition [68,69]. The chaperone network's archi-
tecture makes the potential for cross-talk and compensation enor-
mous. It also explains the disappointing lack of power seen for
elevation of any single heat shock protein as an independent predic-
tor of outcome in cancers. To address this problem, we are exploring
activation of Heat Shock Factor 1 (HSF1), the major transcriptional
regulator of inducible expression for the entire heat shock network
as an indicator of the relative level of “oncogenic” stress within a par-
ticular tumor and consequently the “load” on the HSP90-based chaper-
onemachinery [70,71]. HSF1 statuswill bemonitored in a soon-to-open
clinical trial involving patients with metastatic breast cancer to deter-
mine whether patients with evidence of activation in their tumors are
more or less likely to derive clinical beneﬁt from HSP90 inhibition.
By acutely re-drawing the genotype–phenotype map and limiting
the ability to adapt and respond, HSP90 inhibition could prevent the
outgrowth of resistant clones. On a cautionary note, however,
compromising HSP90 function alone in advanced malignancies, espe-
cially to a sub-lethal extent could work to reveal their underlying ge-
notypic diversity and increase epigenetic instability, thereby
accelerating the process of cancer initiation and malignant progres-
sion in highly unpredictable ways. The potential of kinase inhibitors
to drive the development of secondary skin tumors has been demon-
strated in recent clinical trials of vemurafenib and sorafenib [72,73].
No such events have been reported so far in the development of
HSP90 inhibitors, but work is underway by us and others to better de-
ﬁne the role(s) of HSP90 in cancer evolution as well as the develop-
ment of drug resistance.
2.2.2. Lessons from fungi
Direct evidence supporting a critical role for HSP90 in buffering
genetic variation and enabling the evolution of drug resistance is
emerging from experimental models involving fungi. Many funda-
mental biological processes and molecular pathways are conserved
between human cancer cells and these rapidly proliferating eukaryot-
ic organisms including an absolute requirement for HSP90 function to
survive. In the model organism Saccharomyces cerevisiae, otherwise
unapparent genetic variation in out-crossed strains can be revealed
at the phenotypic level by exposure to HSP90 inhibitors in a strain-
speciﬁc manner [74,75]. In other ecologically and genetically diverse
yeast species, HSP90-dependent traits have been shown to be both
common and frequently adaptive. Most are based on preexisting ge-
netic variation, with causative polymorphisms occurring in coding
and regulatory sequences alike [62]. In regard to drug resistance, mu-
tations in pathogenic fungi which confer resistance to structurally
and mechanistically distinct antifungals create new dependencies
on HSP90 and the cellular stress signaling pathways which it supports
[76,77]. When HSP90 function is compromised either genetically or
with inhibitors, de novo emergence of resistance to the commonly
used antifungal ﬂuconazole is eliminated (Fig. 2). Likewise, exposure
to concentrations of an HSP90 inhibitor which have no apparent anti-
fungal activity of their own can restore sensitivity to ﬂuconazole and
caspofungin in resistant clinical isolates of Candida albicans and As-
pergillus fumigatus respectively [76,77]. The enormous genetic dis-
tance between these divergent fungal species argues for an ancient,highly conserved biology that very likely applies to human cancer
cells as well. Also of potential relevance to cancer treatment, resis-
tance emerging as a result of acute exposure to high, therapeutic an-
tifungal concentrations was found to involve HSP90-dependent
mechanisms while resistance evolving slowly as a result of exposure
to gradually increasing antifungal concentrations was typically drug
efﬂux pump-mediated and HSP90-independent [78].
2.2.3. Acquired resistance to HSP90 inhibitors
While the frequent emergence of target-related resistance has
been seen during the clinical development of many kinase inhibitors,
no drug-resistant HSP90 mutations have been reported in patients
with advanced cancers, even after prolonged exposure. Pre-clinical
studies have shown that reduced expression of the oxidoreductase
NQO1 can confer resistance to quinone-containing ansamycin
HSP90 inhibitors such as 17-AAG, but no cross-resistance to other
classes of inhibitor has been seen [79]. Ansamycin-based inhibitors
are also substrates for P-glycoprotein-mediated drug efﬂux which is
a concern in cancer cells of multi-drug resistance (MDR) phenotype
[80]. A naturally occurring single amino acid change in the ATP-
binding pocket of HSP90 from the fungus Humicola fuscoatra has
been reported to confer resistance to radicicol and other resorcinol-
based synthetic HSP90 inhibitors [81]. Such a mutation has not been
reported in any pre-clinical or clinical studies to date. Compensatory
responses and epistatic alterations in other components of the
HSP90-based chaperone machinery could lead to diminished drug
sensitivity, but this mode of functional resistance may be quite dy-
namic and will be difﬁcult to document in the clinical setting. For
now at least, the acquisition of high level, directly target-related resis-
tance to HSP90 inhibitors does not seem to be a major contributor to
the problem of their limited activity against recurrent, refractory can-
cers in most clinical trials to date.
2.2.4. Optimizing therapeutic efﬁcacy
Therapeutic efﬁcacy as reﬂected in clinical beneﬁt is determined
not just by direct anticancer activity but also by the speed and fre-
quency with which resistance occurs. Activity and resistance are not
independent variables (Fig. 1). The greater the log cell kill induced
by a drug, the smaller the residual tumor burden in which resistance
can develop. Likewise, even if a compound possesses relatively weak
anticancer activity, if resistance does not occur, it can still be an effec-
tive agent. Historically, these considerations have been the basis for
the design and use of combination therapies for the treatment of dis-
eases ranging frommicrobial infection to cancer [82]. Ideally, by com-
bining appropriate drugs, net activity can be increased and non-cross
reactive mechanisms of action will make the development of resis-
tance less likely. Counter intuitively, however, theoretical models
and new experiments now suggest that antagonistic interactions be-
tween antibiotics, even at the expense of reducing net activity can ac-
tually counteract the evolution of drug resistance in bacteria [83,84].
Whether similar effects would be operative in cancers is unknown,
but it does highlight the difference between optimizing activity and
actually improving efﬁcacy in the design of drug combinations. Driving
a greater reduction in tumor volume by combining HSP90 inhibition
with other agents may be less relevant to clinical efﬁcacy than extend-
ing the duration of disease control that can be achieved.
3. Clinical experience
Over a dozen HSP90 inhibitors are undergoing clinical testing, ei-
ther as single agents or in combination with cytotoxic or molecularly
targeted drugs (Table 1). Pivotal trials to support approval of an FDA-
licensed indication for tanespimycin, the most advanced agent, how-
ever, have recently been suspended by the sponsor for non-clinical
reasons [85]. Although much progress is being made, no HSP90 inhibi-
tor has yet achieved an approved indication in the treatment of cancer.
Fig. 2. Modest HSP90 inhibition prevents the emergence of antifungal drug resistance.
The opportunistic fungal pathogen Candida albicans was plated on agar dishes supple-
mented with the conventional antifungal ﬂuconazole, the classical HSP90 inhibitor
radicicol or both compounds as indicated. Images were acquired 2 days post plating.
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Geldanamycin, a benzoquinone ansamycin, is the prototypical
HSP90 ATPase inhibitor. Despite dramatic effects in cell culture, its ac-
tivity in preclinical models was limited due to metabolic instability
and dose-limiting hepatotoxicity. In an effort to improve tolerability
and to address formulation issues, a number of semi-synthetic gelda-
namycin derivatives have been developed, including 17-AAG, 17-
DMAG, IPI-504, and ABI-010.
3.1.1. 17-AAG (Tanespimycin)
17-AAG was the ﬁrst HSP90 inhibitor to enter the clinic. In the ini-
tial phase I trials exploring weekly schedules, toxicities included fa-
tigue, nausea, vomiting, diarrhea, and transaminase elevations
[86–88]. The half-life was 4.1 h for 17-AAG and was 7.6 h for 17-AG,
a major active metabolite. Consistent with its mechanism of action,
induction of HSP72 in peripheral blood lymphocytes (PBL) occurred
within 6 h of 17-AAG administration. At 24 h, concomitant depletion
of client proteins was found in most tumor biopsy samples. However,
at 96 h, the expected effects of 17-AAG were not reproducibly demon-
strated, leading to the conclusion that at the studied dose and schedule,
HSP90 inhibition persists between 24 and 96 h. Indeed, in a subsequent
phase II trial in patientswithmetastaticmelanoma, sustained inhibition
of theMAPK pathwaywas not observed in post-treatment biopsies, and
no patient achieved an objective response [89].
These and other data prompted exploration of a twice weekly
schedule (given two weeks out of three), which was associated with
consistent HSP72 induction in PBLs during the treatment weeks
[90]. However, grade 3/4 reversible transaminase elevations were
reported in nearly half of patients. Continuous twice-daily dosing
was not feasible due to delayed hepatotoxicity [91]. Daily schedules
(5 days every 3 weeks) have also been explored [91,92]; however,
continuous IV daily dosing is not practical in the clinic, and breaks be-
tween cycles limit the goal of more sustained HSP90 inhibition.
An important limitation has 17-AAG has been formulation. 17-AAG
is not water-soluble and requires a diluent including egg phospholipid
and 4% DMSO. Hypersensitivity reactions were observed in the phase I
trial. Furthermore, the amount of DMSO administered in a single infu-
sion was as high as 40 mL, which may have contributed to the toxicity
proﬁle and led to a persistent odor that may have had a negative effect
on quality of life. Despite improvements in formulation and promisingevidence of activity for combination regimens incorporating the agent
in breast cancer and multiple myeloma, the clinical development of
17-AAG has recently been discontinued by its sponsor, Bristol-Myers
Squibb [93].
3.1.2. Water-soluble ansamycins: 17-DMAG and IPI-504
In attempts to overcome formulation problems, 17-DMAG and IPI-
504 have been developed as water-soluble analogs of 17-AAG. In addi-
tion to its solubility, 17-DMAG ismore active than 17-AAG in preclinical
models and has the potential for oral bioavailability. 17-DMAGhas been
explored at a variety of doses, schedules, andmethods of administration
(i.e. oral or I.V.). On two daily intravenous schedules (3 consecutive or 5
consecutive days on a 21-day cycle), 9% of patients experienced unex-
pected grade 3/4 pneumonitis [94]. Furthermore, reliable depletion of
client proteins in 24-hour biopsies was not observed. When given on
a weekly schedule, DLT occurred in two patients treated at the
106 mg/m2 dose, including one treatment-related death characterized
by rapid (within 24 h) onset of grade 4 transaminitis and eventual hy-
potension, acidosis, and renal failure [95]. While better tolerated at
the 80 mg/m2 dose, grade 1/2 ocular toxicities were observed in four
patients, including blurred vision, keratitis, and ocular surface disease.
In contrast to the daily schedule, sustained induction of HSP72 was ob-
served in PMBCs, and client protein depletion was observed in the
tumor tissues. Two patients achieved an objective response (1 prostate,
1 melanoma) and 3 patients experienced prolonged stable disease
(chondrosarcoma, renal cell cancer and prostate cancer). Ultimately,
17-DMAG development has been limited by uncertainty in the optimal
trade-off between dose (higher doses seem, based on limited tissue
samples, to be associated with more reliable target inhibition and
expected downstream effects), frequency of administration, and toxici-
ty [96].
IPI-504 (retaspimycin) is a water-soluble form of 17-AAG. In
vivo, IPI-504 exists in equilibrium with 17-AAG. IPI-504 has reached
phase II and III clinical trials. However, similar to 17-AAG and 17-
DMAG, hepatotoxicity has been observed. For example, in a ran-
domized, phase III trial of IPI-504 conducted in patients with gastro-
intestinal stromal tumors (GIST), four on-treatment deaths were
observed, leading to early closure of the study after 47 of 195
planned patients were enrolled [97]. Three of the four patients had
grade 3 or 4 transaminase elevations. Notably, in this study, about
20% of patients had had prior hepatic resections, which may have
contributed to the excess toxicity observed. In contrast, in a phase
II study of 76 heavily pre-treated patients with NSCLC at the same
dose and schedule, IPI-504 had an acceptable safety proﬁle, with in-
frequent (5–9%) grade 3 transaminase elevations [38]. In a phase II
study among 26 patients with HER2-positive breast cancer treated
at 300 mg/m2 once weekly, grade 3 transaminase elevation was ob-
served in only 1 patient, other grade 3 toxicities were rare, and no
grade 4 toxicities were observed [98]. Thus, it appears that the tox-
icity proﬁle of IPI-504 is dose and schedule dependent, and further
dose escalations to improve the depth or duration of HSP90 inhibi-
tion may not be possible.
3.2. Second- and third-generation HSP90 inhibitors
Extensive efforts from both academic and industrial groups have
resulted in the discovery and pre-clinical testing of an array of new
synthetic inhibitor chemotypes [99]. Several of these new classes of
compounds are being developed in an attempt to reduce the most
prominent liabilities associated with ﬁrst generation HSP90 inhibi-
tors. These compounds share the ability to bind the N-terminal
ATPase site of HSP90 with higher afﬁnity than the natural nucleotides
and prevent the chaperone from cycling between its ADP- and ATP-
bound conformations. Of these, AUY922 (Novartis) and STA-9090
(Synta) are furthest in development.
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Common adverse effects of AUY922 have included diarrhea, nau-
sea, fatigue, and vomiting [100]. Ocular toxicities, including blurred
vision, darkening of vision, and delayed dark/light accommodation
have also been observed, though have usually been relatively mild
and reversible. Although the mechanism remains unclear, such toxicity
has been a recurrent issue for HSP90 inhibitors and has led to discontin-
uation of development for the Pﬁzer compound SNX-5422 [101]. In a
Phase I trial of AUY922, stabilization of disease was observed, as were
metabolic (FDG-PET) responses. Preliminary evidence of monotherapy
activity has also been observed in a phase 2 trial of ER+orHER2+met-
astatic breast cancer patients [102]. Numerous phase 2 monotherapy
and combination trials are under way across a variety of malignancies.
3.2.2. STA-9090
STA-9090 (ganetespib) has reached phase III clinical trials. In
phase I testing, the toxicity proﬁle has been similar to AUY922,
though ocular toxicity appears to be less frequently reported. Single
agent clinical activity was observed in heavily pretreated NSCLC,
breast cancer (both HER2-positive and triple-negative), gastric can-
cer, melanoma, and colon cancer. The most common adverse event
has been transient diarrhea, which has been manageable with stan-
dard care. A Phase IIb/III trial in NSCLC has been recently initiated;
Phase II trials in breast cancer, colon cancer, gastric cancer, melanoma
and others are underway (see Table 1 and [37]).
3.2.3. Others
A range of additional chemotypes are in clinical development. Some
such as MPC3100 (Myriad Pharmaceuticals) are orally bio-available,
which could provide a real practical advantage given the issues of dose
and schedule that have complicated the development of compounds re-
quiring parenteral administration. Another advantagemay be the poten-
tial for more continuous, sustained HSP90 inhibition, but this remains to
be demonstrated. Several new agents show good central nervous system
(CNS) penetration which could expand their range of potential indica-
tions to include primary brain tumors and CNS metastases.
In addition to small molecules that bind the N-terminal ATPase
site of HSP90, several alternative approaches to HSP90 inhibition
have been reported, but none of these are appropriate yet for clinical
development. For example, the peptidomimetic compound shep-
herdin was designed to disrupt the interaction of the anti-
apoptotic protein survivin with Hsp90. Shepherdin makes extensive
contacts within the N-terminus of Hsp90 and can destabilize several
Hsp90 client proteins as well as survivin. It is cell-permeable and selec-
tively induces apoptosis in tumor cells [103]. An intriguing variation on
the classical HSP90 inhibitor 17-AAG is a derivative designed to accu-
mulate in mitochondria and inhibit the pool of HSP90 found in this
compartment only in cancer cells where it plays an essential anti-
apoptotic role [104,105]. Novobiocin, a coumarin-based inhibitor of
bacterial DNA gyrase binds to HSP90's putative C-terminal ATP binding
site and alters HSP90 conformation thereby impairing HSP90-client in-
teractions and possibly dimerization, albeit only at relatively high con-
centrations [106,107]. Novobiocin derivatives that possess better
potency and HSP90 selectivity have been developed [108] and anti-
cancer activity in a mouse model of head and neck cancer has been
reported [109].
3.3. HSP90 inhibitors asmonotherapy inmolecularly deﬁned cancer subsets
3.3.1. Non-small cell lung cancer
Non-small cell lung cancer is an attractive target for HSP90 in-
hibitors. Targeted inhibitors of EGFR and ALK have shown consider-
able activity in molecularly-deﬁned populations. However,
resistance almost invariably develops in the metastatic setting. Es-
cape mechanisms include the T790M mutation in EGFR, but can
also be related to cross-talk with other pathways or activation ofdownstream effectors. Hypothetically, HSP90 inhibitors may over-
come these and other resistance mechanisms as discussed above
in Section 2.2.
A phase II trial of IPI-504 was conducted in 76 patients with stage
IIIB or stage IV NSCLC who had previously progressed on an EGFR ty-
rosine kinase inhibitor [38]. The study was designed to evaluate the
primary endpoint of objective response rate in each of two arms:
EGFR mutant and EGFR wild-type. In this heavily pre-treated cohort
(median of 4 prior systemic regimens), responses were observed in
10% of EGFR wild-type patients and only 4% of patients with EGFR
mutant tumors. In a post-hoc analysis, two of three patients with
the EML4–ALK rearrangement achieved a PR and the third patient
had prolonged stable disease. Findings in the EML4–ALK population
have recently been conﬁrmed in a trial of the fully synthetic HSP90
inhibitor STA-9090, where 4 out of 8 patients with the EML4–ALK
rearrangement achieved an objective partial response, supporting a
class effect [110]. Notably, preclinical models of acquired crizotinib
resistance via ampliﬁcation or secondary mutations of EML4–ALK
still demonstrate sensitivity to 17-AAG [111].
Why might the activity of HSP90 inhibitors as single agents in NSCLC
be apparently limited to patients with EML4–ALK rearrangements? The
EML4–ALK fusion protein appears to be exquisitely sensitive to HSP90 in-
hibition and, in the setting of tumor addiction to the fusion protein, activ-
ity is seen [112]. Indeed, results of a recently reported phase II trial of the
fully synthetic HSP90 inhibitor STA-9090 largely recapitulate the results
of the IPI-504 trial. Alternatively, it has been suggested that the EML4–
ALK fusion could simply be a favorable prognostic factor associated
with longer progression-free survival in NSCLC patients, independent of
speciﬁc treatment [113]. Another possibility is that mutant EGFRmay re-
quire longer and more sustained depletion, and the “off weeks” required
for IPI-504 and STA-9090 allow for resistance to occur. Finally, these trials
testedHSP90 inhibitors in patientswith EGFR-mutant tumors resistant to
EGFR TKIs, and it is possible that HSP90 inhibitors as monotherapy are
simply not sufﬁcient to overcome the multiple resistance pathways that
develop. This leads to the question of whether HSP90 inhibitors might
more fruitfully be studied in combination with EGFR TKIs, where con-
current administration might delay the emergence of resistance, either
by direct inhibition of resistance pathways, or by limiting the ability of
tumor cells to adapt and respond as seen in the case of antifungal
drug resistance (Fig. 2). In the case of EML4–ALK, (e.g. the subtype sen-
sitive to HSP90 inhibitors), the next logical question is whether com-
bined therapy with crizotinib plus an HSP90 inhibitor provides a
better response rate and/or more prolonged disease control compared
to either agent alone.3.3.2. Melanoma and BRAF
Oncogenic BRAF, most commonly the V600Emissense mutation, is
present in 40–60% of melanomas [114,115] and leads to activation of
the MAPK pathway. As RAF (both RAF1 and BRAF) and MAPK, among
others, are HSP90 client proteins, it would seem logical that HSP90 in-
hibitors might have considerable activity against melanoma. Indeed,
evidence of prolonged stable disease and a few scattered objective re-
sponses have been observed in phase I studies [86,95]. However, in a
phase II trial of weekly 17-AAG in patients withmetastatic melanoma,
no objective responses were observed among 15 patients, including 9
with BRAF mutations. Notably, although post-treatment biopsies did
show evidence of HSP70 induction, there was no signiﬁcant effect of
17-AAG on BRAF kinases or phospho-ERK expression [89]. Based on
these data, it is not possible to draw deﬁnitive conclusions about
the status of HSP90 inhibitors for melanoma, and points to the impor-
tance of post-treatment tumor biopsies in understanding the adequa-
cy of target inhibition and its downstream effects. It is still an open
question whether more potent inhibitors, either alone, or more likely,
given in combination with B-RAF kinase inhibitors might provide
more robust evidence of clinical activity.
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3.3.3.1. Disappointing single agent results. Renal cell carcinoma (RCC)
would seem a logical malignancy in which to evaluate HSP90 inhib-
itors, given the efﬁcacy of agents targeting VEGF/VEGFR (bevacizumab,
sunitinib), mTOR (everolimus, temsirolimus) and multi-targeted
agents (sorafenib). One might hypothesize that HSP90 inhibitors
would be particularly effective “multi-kinase inhibitors”, given its
mechanism of action, and have activity in RCC. However, a phase II
trial of 17-AAG was negative, with no objective responses in 20 pa-
tients [116]. Whether this was due to insufﬁcient depletion of target
proteins or because HSP90 is not a valid target in RCC is difﬁcult to
know for certain.
HSP90 inhibitors are also associated with depletion of the andro-
gen receptor and have anti-proliferative activity in mouse xenograft
models of prostate cancer. A two-stage, single arm, phase II trial of
17-AAG (300 mg/m2 weekly for 3 of 4 weeks) was initiated in pa-
tients with castration-resistant prostate cancer [117]. No PSA re-
sponses were observed and the study was therefore terminated
after the ﬁrst stage of enrollment. As in RCC, whether the lack of activity
truly reﬂects lack of validity of HSP90 as a target in prostate cancer, ver-
sus liabilities from ﬁrst generation drug pharmacokinetics/pharmaco-
dynamics is uncertain at this time. In addition, it is possible that
combining HSP90 inhibitors with standard agents targeting the andro-
gen receptor or with chemotherapy might provide efﬁcacy not seen
with single agent therapy.3.4. Combination therapy
3.4.1. HER2-positive breast cancer
3.4.1.1. Targeting an oncoprotein and downstream pathways. Given
that HER2 is one of the most HSP90-depedent client proteins
known, HSP90 inhibitors are being actively studied in this tumor
type, both alone and in combination with the HER2-targeted
monoclonal antibody trastuzumab. HSP90 inhibitors also lead to
depletion of many downstream members of the HER2 signaling
pathway. Therefore, it has been hypothesized that HSP90 inhibi-
tion could potentially delay or reverse the development of trastu-
zumab resistance.
Promising activity in a phase I study combining 17-AAG with tras-
tuzumab has led to several phase II studies in this patient population
[118]. In a phase II trial of 17-AAG with trastuzumab, the objective re-
sponse rate was 22% in patients with metastatic, HER2-positive breast
cancer who had progressed on prior trastuzumab therapy [119]. Pro-
longed stable disease and minor responses were observed in a phase
II study of IPI-504 with trastuzumab; however, that study was termi-
nated early (after the ﬁrst stage of accrual) because it did not reach
the protocol-speciﬁed threshold of efﬁcacy [98]. Notably, patients in
this IPI-504 study were heavily pre-treated, with a median of 6
prior lines of chemotherapy for advanced disease. Based on these re-
sults, HER2-positive breast cancer remains an area of active clinical
trials with the newer HSP90 inhibitors. A key question to be
addressed is whether or not continued administration of trastuzumab
in combination with HSP90 inhibitor is important for the activity that
has been observed. It may be essential to maintain pressure on the
signaling axis by continuing trastuzumab even though high level re-
sistance to the antibody has been established. Precedent is provided
by a recent study in which combination of the small molecule HER2
kinase inhibitor lapatinib and trastuzumab was superior to lapatinib
alone in patients who had previously progressed on trastuzumab
[120]. A related, very important question would be whether up-
front combination therapy with trastuzumab and HSP90 inhibitor
can prevent or delay the emergence of trastuzumab-resistance in
naïve HER2-positive patients.3.4.2. Multiple myeloma: targeting the proteasome
The proteasome has been demonstrated to be a valid and effective
target in multiple myeloma. Thus, an attractive combination involves
HSP90 inhibitors with the proteasome inhibitor bortezomib. Pre-
clinical data indicate that combined therapy leads to synergistic sup-
pression of the activity of the 20S proteasome and increased proteo-
toxic stress in tumor cells. Anti-tumor activity was seen in a phase I
monotherapy trial of 17-AAG [121]. Notably, in a phase II combina-
tion study with bortezomib, conducted in heavily pre-treated refrac-
tory or relapsed patients, promising activity was observed [121]. Of
relevance to this and other potential combinations, 17-AAG appeared
to ameliorate the neuropathy often observed with bortezomib. An on-
going combination trial with AUY922 will be of interest to follow as
results become available.
3.4.3. Combinations with conventional chemotherapy
Combinations with several classes of cytotoxic agents as described
in Section 2.1.1 have now reached clinical trial. Docetaxel is being
combined with IPI-504 in a randomized phase II trial in NSCLC, and
STA-9090 is currently in phase III testing in the same setting. Other
combinations are considerably earlier in development and primarily
involve ﬁrst-generation HSP90 inhibitors. Examples include DNA-
damaging agents such as the platinums which pre-clinical mechanis-
tic insights suggest should enhance the activity of HSP90 inhibitors.
Unfortunately, increased hematopoietic toxicity was seen for the
combination of tanespimycin with cisplatin and no dose could be
recommended for phase II testing [122]. A phase I study of the topo-
isomerase I inhibitor irinotecan in combination with tanespimycin
found acceptable toxicity and some tumor shrinkage in patients
with refractory solid tumors [12]. Phase I studies of tanespimycin
and anti-metabolite nucleoside analogs such as gemcitabine and
cytarabine have been reported in both hematopoietic malignancies
and solid tumors [122,123]. As trials progress and efﬁcacy data become
available, it will be of great interest to determine whether beneﬁts for
cytotoxic combinations are seen in speciﬁc molecular subgroups as
has been the experience with kinase inhibitors and whether molecular
classiﬁcation can be used to help guide patient selection .
4. Concluding thoughts
The concept of combining drugs to increase the likelihood of cure
has a long history in the treatment of infectious diseases and cancer.
With the exceptions of choriocarcinoma and Burkitt's lymphoma,
treatment with single agents has never been able to produce either
signiﬁcant remissions or to cure patients with disseminated cancer
[124]. The principles of combining drugs with non-cross reactive
modes of action and non-overlapping toxicities to prevent the emer-
gence of resistance and consequent treatment failure were formalized
in the quantitative mathematical modeling developed by Goldie and
Coldman in the early 1980s [125]. They have guided the ﬁeld ever
since. In this sense, the idea of combining HSP90 inhibitors with
other drugs to assemble more effective chemotherapy regimens is
an obvious next step. The novelty of the work discussed in this review
resides in the possibility that HSP90 inhibitors provide not only a new
mode of anticancer action, but might for the ﬁrst time provide a way
to limit the intrinsic evolvability of cancers. While far from certain, if
clinical trials are not designed to detect such an effect, it certainly
won't be found. Likewise, if development of HSP90 inhibitors is aban-
doned because they don't shrink advanced cancers when given as sin-
gle agents, a valuable opportunity to test the hypothesis that genetic
heterogeneity and attendant evolvability can be controlled in clinical
cancers.
Major limitations of ﬁrst generation inhibitors have impaired the
ability to test combinations due to dosing constraints and prominent
off-target effects. Next generation compounds are now making it fea-
sible in concept to critically address many key questions for the ﬁrst
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level HSP90 inhibition than IV dosing. Continuous but modest
HSP90 inhibition may not exhibit dramatic single agent activity, but
it could alter the tumor landscape in ways sufﬁcient to enhance the
magnitude and duration of response to other agents without increas-
ing systemic toxicity. Viewed in this light, induction of the heat shock
response in systemic tissues might represent an indicator of acute
toxicity. Rather than a target pharmacodynamic endpoint to conﬁrm
adequate drug exposure as employed in most clinical trials to date,
the induction of HSP72 in peripheral blood lymphocytes might actually
be something to be avoided, at least in the development of continuous
dosing regimens for oral HSP90 inhibitors in combination with other
drugs.
Many new and exciting concepts are ready to test, but practical is-
sues will arise, especially in performing trials that involve combining
agents that are proprietary to highly competitive pharmaceutical
companies [126,127]. It is going to require a willingness on the part
of regulatory agencies, pharmaceutical ﬁrms and clinicians to think
about things in a different way, but the rewards could be great in ad-
vancing our understanding of cancers and beneﬁtting patients suffer-
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